“反饥饿游戏”:随着肥胖患者的愤怒,药房的 Zepbound 供应量减少
"Anti-Hunger Games": Zepbound Supplies At Pharmacies Dwindle As Obese Patients Rage

原始链接: https://www.zerohedge.com/medical/anti-hunger-games-zepbound-supplies-pharmacies-dwindle-obese-patients-rage

由于全国范围内的短缺,诺和诺德公司的减肥药 Wegovy 和礼来公司的 Zepbound 越来越受到超重美国人的欢迎。 CVS、沃尔格林和沃尔玛的药剂师报告称,Zepbound 在各州出现缺货情况。 像 Shannon Lucero 和 Rachael Altenburg 这样的患者很难找到能够配药的药房。 肥胖诊所在需求不断增加的情况下,只能在有限的资源中周旋,这让患者和医疗专业人员都感到沮丧。 据行业专家称,到本世纪末,超过 1500 万美国人可能会使用这些 GLP-1 药物。 两家公司都认识到制造需求的增加,并计划进行扩张以满足不断增长的需求。 尽管有人说 Zepbound 库存不足,但美国食品和药物管理局坚称仍有足够数量。 批评者质疑,当营养和运动仍然是可行的替代方案时,为什么医疗保健会优先考虑药物。

相关文章

原文

Obese Americans have flocked to weight loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Surging demand for both drugs has led to shortages across the country. 

Bloomberg spoke with nine pharmacists and technicians at CVS, Walgreens, and Walmart in six states, who said Zepbound was on backorder.

Shannon Lucero failed to fill her Zepbound prescription at eight pharmacies in San Diego, California. One pharmacy responded and said the GLP-1 drug was out of stock until the end of the first week of April. 

In Monroe, Michigan, Rachael Altenburg spent days searching for pharmacies to fill her order for the weight loss drug. 

Angela Fitch, who operates an obesity clinic in Boston, said the supply situation for GLP-1 drugs is painful for patients and doctors due to limited supply and soaring demand. 

"Patients are mad at my staff, my staff are upset," Fitch said in an interview, adding one of her patients had to spend the day and call pharmacies around the Boston metro area, and after hours of calling, finally found one that could fill her prescription. 

"It's like The Hunger Games," she said, adding, "Well, actually more like the anti-Hunger Games."

Goldman analysts recently told clients that upwards of 15 million Americans could be on GLP-1 drugs by the end of the decade. Other Wall Street analysts forecast the weight loss drug market could be worth $100 billion by 2030. 

Novo Nordisk and Eli Lilly have communicated to investors that production of their GLP-1 drugs will be ramped up after a round of new investments into production facilities this year. 

"We cannot supply to an uptake that just continues growing," Novo Nordisk CEO Lars Fruergaard Jorgensen told investors during a conference call earlier this month. He said lower-strength starter doses for the US market are necessary to safeguard supplies for current patients. 

Despite patient reports and pharmacies telling Bloomberg that Zepbound supplies are either low on stock or out, an FDA spokesperson said, based on the current information from Lilly, "there is currently adequate supply" of the weight loss drug. 

It seems like the American healthcare system's only solution to obesity is a miracle drug. After all, there's no money for big pharma and doctors to tell obese folks that eating healthy and working out is a safe alternative to taking drugs. 

联系我们 contact @ memedata.com